- Russia mulls ban on 'childless propaganda'
- Blackwater founder probed by Venezuela over anti-Maduro campaign
- Crypto CEO and Bankman-Fried ex Caroline Ellison gets two-year sentence
- Hezbollah announces death of commander after strike on south Beirut
- Tatum hungry for more after breakthrough Celtics success
- Sean 'Diddy' Combs sued for alleged 2001 rape
- New York area port prepares for possible US strike disruption
- Rodri 'irreplaceable' but Guardiola confident Man City will still compete
- Mbappe strikes again as Madrid hold off Alaves
- Nkunku hits Chelsea hat-trick, Man City edge into League Cup last 16
- Amnesty calls for commission to probe Kenya protest deaths
- Bolivian government rejects Morales ultimatum for cabinet reshuffle
- US Congress calls on Novo Nordisk to lower drug prices
- Russia 'can only be forced into peace," Zelensky tells UN
- Biden pleads for democracy in final UN address
- Brook's hundred sees England beat Australia in 3rd ODI
- Alarm grows as Israel and Hezbollah exchange intense fire
- NFL legend Favre reveals Parkinson's diagnosis
- Biden urges world to 'stop arming generals' in Sudan
- Defying experts, Trump vows tariff-driven US economic boom
- Stokes open to England white-ball return
- No peak oil demand 'on the horizon', phaseout a 'fantasy': OPEC
- England scrum-half Mitchell to see specialist on neck injury
- Under-pressure Masood to lead Pakistan in England Tests
- Storm Helene on track to hit Florida as major hurricane
- IOC should reinstate Russia as soon it obeys rules: Samaranch
- Dior unleashes arrows and Amazons at Paris Fashion Week
- San Siro loses 2027 Champions League final due to uncertain future
- Canada's Trudeau faces no-confidence vote
- AI research uncovers 300 ancient etchings in Peru's Nazca desert
- Brazil's Lula calls Security Council makeup 'unacceptable'
- Carey blasts Australia to 304-7 against England in 3rd ODI
- Biden warns against clinging to power in UN farewell
- Alarm grows as Israel launches new strikes on Lebanon
- Biden warns at UN against 'full-scale war' over Lebanon
- 'Monumental step' as Thai king signs same-sex marriage into law
- French lake still riddled with bombs 80 years after World War II
- Alberta Ferretti quits as creative director at brand she founded
- Two killed in Mexico as Hurricane John weakens to tropical storm
- Multiple arrests after US woman uses machine-assisted suicide in Switzerland
- Dubois will next fight Joshua or Usyk, 'whoever pays me the most'
- Lopetegui ready to learn from mistakes as Liverpool loom in League Cup
- US Fed dissenter warns inflation risks remain 'prominent'
- UN chief warns Lebanon on 'brink' as world leaders gather
- Surprise start for Libbok as Etzebeth set for Springboks record
- Ten Hag says expanded schedules make injuries 'almost unavoidable'
- Liverpool boss Slot praises Alexander-Arnold's defensive work
- Barca coach backs Pena but will debate new goalkeeper signing
- UN says tens of thousands flee Lebanon strikes
- Arteta stands by defensive tactics in fiery Man City clash
US Congress calls on Novo Nordisk to lower drug prices
The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised Tuesday to examine lowering their prices in the United States, after coming under pressure from Congress.
The stakes are high for US patients, some of whom have difficulty accessing and affording the drugs under the often unwieldy and expensive health care system in the United States.
"If not made affordable, Americans throughout this country will needlessly die," left-wing Senator Bernie Sanders told Novo Nordisk CEO Lars Fruergaard Jorgensen at a congressional hearing.
"Ozempic is sold in Canada for $155, in Denmark for $122, in France for $71, and in Germany for $59. In the United States, Novo Nordisk charges us $969," Sanders continued.
Ozempic was originally developed as a drug to treat diabetes. Wegovy, which targets weight loss, sells for $1,349 a month in the United States, nearly 15 times as much as it costs in the United Kingdom, Sanders continued.
"Will you commit today that Novo Nordisk will substantially reduce the list price of these drugs in the United States, so that the American people are not paying higher prices, far higher prices for these drugs than the people in Europe and Canada?" Sanders asked.
"Anything that will help patients get access to affordable medicine, will be happy to look into," Jorgenson replied -- though he pointed out that 80 percent of Americans with health insurance paid $25 or less a month.
Jorgenson also noted that the high prices were partly driven by other players, namely Pharmacy Benefit Managers (PBMs), who act as intermediaries between insurance companies and drug manufacturers, negotiating discounts and listing covered treatments.
PBMs receive a fee based on list price -- so, "the higher list price, the more fee they get for the same job," Jorgenson said.
"Which means that, in our experience, products that comes with a low list price get less coverage (from health insurers)," he continued.
For example, he said, when Novo Nordisk lowered the cost of insulin treatments, their drugs were taken off the list of medications covered by health care plans, "so less patients got access to those insulins.
"So I have a bit of concern how this could play out," he said.
Sanders replied that he had received promises from three major PBMs not to limit coverage of Ozempic and Wegovy if their prices were lowered.
"Do I have your commitment that you will sit down with the three companies to make sure that they keep that commitment?" he asked Jorgenson.
"Yes, anything that can help patients get access, I'm supportive of," the Danish CEO replied.
US President Joe Biden has previously called for drug prices to be lowered in the United States, saying firms must stop "ripping off the American people."
High prices for prescription drugs have been a long-standing problem for American patients, and Biden has focused on lowering health care costs.
Ferreira--PC